The global Preterm Birth and PROM Testing Market was valued at USD 227.8 million in 2023 and is projected to expand at a CAGR ...

QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...

Last week, readers were most interested in a story about a lawsuit brought forth by Qiagen against BioMérieux in Germany.

QIAGEN has received FDA approval for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its syndromic testing offerings for gastrointestin ...

Qiagen alleges that BioMérieux infringes a European patent that protects the company's QuantiFeron interferon-gamma release assay technology for latent TB detection.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent in ...

(RTTNews) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements behind ...

Today G&GR welcomes long time member and first time contributor, John Tynan, to the writing ranks. Take it away JT: Welcome to The Pub Test, where rugby opinions flow as freely as the beer and ...

Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company ...

The test is designed to screen for genetic markers associated with celiac disease, an autoimmune condition affecting the intestine. Credit: Jo Panuwat D / Shutterstock. The US Food and Drug ...

The Supreme Court recently acquitted an accused after noting that the person who witnessed the accused during the Test Identification Parade (“TIP”) was not examined during the trial.